Resources

 

Download important information about PROS (PIK3CA-Related Overgrowth Spectrum)

 

PROS Fact Sheet

Learn about the genetic cause, diagnosis, and current landscape of PROS and its associated disorders.

Download >

 

Access relevant patient advocacy groups

 

CLOVES Syndrome Community

Find resources, educational materials, a patient-led research network, and support for people with CLOVES syndrome and their families.

Click here >

 

K-T Support Group

Find resources and support for people with Klippel-Trenaunay Syndrome and related conditions.

Click here >

 

M-CM Network

Find information, resources, and patient-centered research for people with M-CM and their families.

Click here >

 

All organizations listed are not-for-profit and/or government agencies, and are independent from Novartis Pharmaceuticals Corporation. Novartis has no financial interest in any organization listed, but may provide occasional funding support to these organizations. All descriptions are copyright of the respective organizations.

Find more information below

Discover more about PROS Understand the impact of PROS on patients See how to diagnose PROS Learn about PROS management landscape Find useful resources

PROS disorders:

  • KTS (Klippel-Trenaunay Syndrome)
  • CLOVES syndrome (Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/skeletal and spinal)
  • ILM (Isolated Lymphatic Malformation)
  • MCAP or MCM (Megalencephaly-Capillary Malformation)
  • HME (HemiMegalEncephaly)/DMEG (Dysplastic MEGalencephaly)/Focal cortical dysplasia type II
  • HHML (HemiHyperplasia-Multiple Lipomatosis)
  • FIL (Facial Infiltrating Lipomatosis)
  • FAVA (FibroAdipose Vascular Anomaly)
  • Macrodactyly
  • Muscular HH (HemiHyperplasia)
  • FAO (FibroAdipose hyperplasia or Overgrowth)
  • CLAPO syndrome (Capillary malformation of the lower lip, Lymphatic malformation of the face and neck, Asymmetry of the face and limbs, and Partial or generalized Overgrowth)
  • Epidermal nevus, benign lichenoid keratosis, or seborrheic keratosis
  • Other disorders may be identified and characterized as PROS
Learn more

You are now leaving the Novartis site and moving to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or click OK to continue.

1/17 ONC-1154329

Contact Us Site Map

This is a global website and is intended for health care professionals. The information on this site is intended for educational purposes only and is not country-specific.

 

Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2020 Novartis AG. All rights reserved.

4/20 G-ALP-1229003